Risk factors and modes of failure in the modern dual mobility implant. A systematic review and meta-analysis

Fu-Yuan Pai¹,², Hsuan-Hsiao Ma¹,², Te-Feng Arthur Chou¹,², Tsan-Wen Huang³,⁴, Kuo-Chin Huang³,⁴, Shang-Wen Tsai¹,², Cheng-Fong Chen¹,²* and Wei-Ming Chen¹,²

Abstract

Background: The aims of this meta-analysis were to: (1) validate the outcome of modern dual mobility (DM) designs in patients who had undergone primary and revision total hip arthroplasty (THA) procedures and (2) to identify factors that affect the outcome.

Methods: We searched for studies that assessed the outcome of modern DM-THA in primary and revision procedures that were conducted between January, 2000 to August, 2020 on PubMed, MEDLINE, Cochrane Reviews and Embase. The pooled incidence of the most common failure modes and patient reported outcomes were evaluated in patients who have received: (1) primary THA, (2) revision THA for all causes or (3) for recurrent dislocation. A meta-regression analysis was performed for each parameter to determine the association with the outcome. The study design of each study was assessed for potential bias and flaws by using the quality assessment tool for case series studies.

Results: A total of 119 studies (N= 30016 DM-THAs) were included for analysis. The mean follow-up duration was 47.3 months. The overall implant failure rate was 4.2% (primary: 2.3%, revision for all causes: 5.5%, recurrent dislocation: 6.0%). The most common failure modes were aseptic loosening (primary: 0.9%, revision for all causes: 2.2%, recurrent dislocation: 2.4%), septic loosening (primary:0.8%, revision for all causes: 2.3%, recurrent dislocation: 2.5%), extra-articular dislocation (primary:0.6%, revision for all causes:1.3%, recurrent dislocation:2.5%), intra-prosthetic dislocation (primary:0.8%, revision for all causes:1.0%, recurrent dislocation:1.6%) and periprosthetic fracture (primary: 0.9%, revision for all causes:0.9%, recurrent dislocation:1.3%). The multi-regression analysis identified younger age (β=-0.04, 95% CI -0.07 – -0.02) and female patients (β=3.34, 95% CI 0.91–5.78) were correlated with higher implant failure rate. Age, gender, posterolateral approach and body mass index (BMI) were not risk factors for extra-articular or intra-prosthetic dislocation in this cohort. The overall Harris hip score and Merle d’Aubigné score were 84.87 and 16.36, respectively. Level of evidence of this meta-analysis was IV.

* Correspondence: cfchen.vghtpe@gmail.com
¹Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, No. 201, Sec 2, Shi-Pai Road, Taipei 112, Taiwan
²Department of Orthopaedics, School of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan

Full list of author information is available at the end of the article

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Conclusion: Modern dual-mobility designs provide satisfactory mid-term implant survival and clinical performance. Younger age and female patients might impact the outcome after DM-THA. Future research directions should focus on, (1) long-term outcome of modern dual-mobility design, including specific concerns such as intra-prosthetic dislocation and elevated metal ion, and (2) cost-effectiveness analysis of dual-mobility implant as an alternative to conventional THA for patients who are at high risk of dislocation.

Keywords: Dislocation, Dual mobility, Implant failure, Instability, Outcome, Revision total hip arthroplasty, Risk factor, Total hip arthroplasty

Background
Prosthetic dislocation is one of the most common cause of implant failure after total hip arthroplasty (THA) [1]. The reported dislocation rate after primary THAs is 0.3-10% [2–4] and is much higher after revision THAs (5-30%) [5–7]. The cause of a dislocated prosthesis can be multifactorial, including both surgeon and patient related factors [8–18]. Several design changes have been made on the prosthesis to resolve this. Currently, dual mobility (DM) THA is one of the most successful designs to reduce the risk of dislocation [19]. The concept of DM was invented by Gilles Bousquet and André Rambert in France in 1973 [19]. The design included Charnley’s low-friction principle and the theory of McKee and Watson-Farrar, which increased the femoral head-to-neck ratio, extending the “jumping” distance in order to prevent dislocations [20–23]. The first generation DM design was associated with higher aseptic loosening and intra-prosthetic dislocation (IPD) rate, which resulted from polyethylene wear, suboptimal fixation and surface coating of the acetabular component [24–30]. In the late 1990’s, a newer DM design was introduced with several modifications including modular design, shape, surface coating and highly cross-linked polyethylene to reduce the rate of aseptic loosening and IPD [31–34].

Compared with the fixed-bearing THA, several meta-analyses have validated a lower dislocation rate using DM articulation in both primary [35–37] and revision THA procedures [36–39]. Despite the established efficacy of DM articulation in preventing dislocation, it is with clinical importance to validate the overall implant survival and failure modes of this unique design. These studies could only provide results of inferential statistics rather than descriptive statistics with regard to the outcome after DM-THA because the included studies represented only a small number of DM-THA used in primary and revision THA procedures [36–39]. To our knowledge, the most recent and comprehensive systematic review discussing the outcome after DM-THA was conducted by Darrith et al. [40] The authors reviewed studies published from 2007 to 2016, including 54 studies with 14345 primary and revision THA procedures. They reported the overall failure rate (primary: 2.0%, revision: 3.4%) and incidence of common failure modes including aseptic loosening (primary: 1.3%, revision: 1.4%), extra-articular dislocation (primary: 0.46%, revision: 2.2%) and intra-prosthetic dislocation (primary: 1.1%, revision: 0.3%). However, this review included a mixture of the 1st generation and modern (2nd and 3rd generations) DM designs. Several important modes of implant failure such as septic loosening and periprosthetic fracture were not analyzed in this review. Moreover, the number of articles regarding the outcome of modern DM-THA have doubled since 2016 [41–115]. Therefore, an up-to-date meta-analysis is essential to validate the outcome of modern DM-THA. Our primary objective was to identify the overall implant failure rate and several common failure modes including aseptic loosening, septic loosening, extra-articular dislocation, intra-prosthetic dislocation and periprosthetic fracture. The secondary objective was to determine risk factors predisposing to implant failure and the functional performance of these patients after surgery.

Methods
We completed a comprehensive search on PubMed, MEDLINE, Cochrane Reviews and Embase for studies that reported outcome in patients who had undergone dual mobility total hip arthroplasty (DM-THA) published from the earliest record to August, 2020. The search was completed in accordance to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement. The following terms were used in variable combinations: total hip arthroplasty, total hip replacement and dual mobility. Two authors (FYP, SWT) independently searched and screened the titles and abstracts for relevant studies. If there was disagreement, a third author (HHM) was consulted for a consensus. The bibliographies of the included studies were manually reviewed for relevant references. The search strategy is shown in Fig. 1.

We included original articles written in English that validated the outcome in patients who had undergone DM-THA for all kinds of indications including primary THA, revision THA or recurrent dislocation. We excluded review articles, letter to the editor, expert opinion, biomechanical studies, articles not written in English, study period earlier than 2000 or studies in
which data were not obtainable. The included studies must contain at least one of the primary (e.g. overall implant failure rate, failure modes including aseptic loosening, septic loosening, extra-articular dislocation, intra-prosthetic dislocation and periprosthetic fracture) or secondary outcome domains (e.g. functional scores). Two authors (FYP, SWT) examined all relevant studies and obtained data from the texts. If none of the above outcome domains can be obtained from the study, then we will exclude the study. For comparative studies (e.g. hemiarthroplasty or THA vs DM-THA), we extracted data from the DM-THA group if possible. If there was uncertainty regarding the data from the study, we contacted the authors for clarifications. Two authors (FYP, SWT) independently evaluated the methodological quality of the included studies using the NIH Quality Assessment Tool for Case Series Studies [118, 119]. To assess the quality of case series study, the highest score on this scale is 9. A score between 7 and 9, 4 and 6, less than 4 were defined as “good”, “fair” and “poor”, respectively. For the quality of case control study, the highest score on this scale is 12. A score between 8 and 12, 5 and 7, less than 5 were defined as “good”, “fair” and “poor”, respectively. If there were disagreement, we consulted a third author (HHM). (Tables 2 and 3) Of the 119 included studies, the methodological quality was considered “good” in 72 (60.5%) studies and “fair” in 47 (39.5%) studies.

Statistical analysis
A meta-analysis of proportions was conducted using the Freeman-Tukey analysis under random-effects model to determine pooled estimates with a 95% confidence interval (CI). A random-effects model was used for differences among studies such as age, sex, surgical approaches, body mass index, indications for THA procedure, implant brand and methodology. A standard multivariate linear regression analysis ($\beta$) was performed to determine potential factors for implant failure or improved functional outcome. We completed all analyses with the Comprehensive Meta-Analysis (CMA) software, version 3 (Biostat, Englewood, New Jersey, USA) and significance was defined as $p < 0.05$.

Results
We identified 1123 studies according to our search strategy. We removed 714 duplicate records and 232 studies after reading the title and abstract. Another 58 studies were excluded after reading the full text as the studies did not meet the inclusion criteria: studies on different
| Author, Year                      | Study design      | No. of THA procedure | Indications   | Mean age (yrs) | Follow up duration (m) | Implant type | A | B | C | D | E | F | G | H |
|----------------------------------|-------------------|----------------------|---------------|----------------|------------------------|--------------|---|---|---|---|---|---|---|---|
| 2020 Tabori-jensen               | Prospective series | 59                   | Primary       | 75             | 24                     | 1            | V | V | V | V | V | V | V | V |
| 2020 Schmidt                    | Retrospective series | 184                | Revision      | 69             | 24                     | 2, 3         | V | V | V | V | V | V | V | V |
| 2020 Rashed                     | Prospective series | 31                  | Primary       | 66.4           | 12                     | 4            | V | V | V | V | V | V | V | V |
| 2020 Nessler                    | Retrospective series | 93                 | Primary       | 65.5           | 32.4                   | 5            | V | V | V | V | V | V | V | V |
| 2020 Laende                      | Retrospective series | 27                 | Primary       | 63             | 36                     | 6            | V | V | V | V | V | V | V | V |
| 2020 Klemt                       | Retrospective series | 42                 | Revision      | 55             | 48                     | 1, 5, 6, 10, 13 | V | V | V | V | V | V | V | V |
| 2020 Hoggett                    | Retrospective series | 28                 | Recurrent dislocation | 80 | 55             | 3, 7         | V | V | V | V | V | V | V | V |
| 2020 Favreau                    | Retrospective series | 40                 | Revision      | 77             | 54                     | 3            | V | V | V | V | V | V | V | V |
| 2020 Dubin                      | Retrospective series | 664                | Primary       | 61.7           | 25                     | 5, 6         | V | V | V | V | V | V | V | V |
| 2020 Dubin (Arthroplasty Today)  | Retrospective series | 142                | Primary       | 67             | 68.4                   | 6            | V | V | V | V | V | V | V | V |
| 2020 de l’Escalopier             | Retrospective series | 84                 | Revision      | 71             | 65.3                   | 8, 9         | V | V | V | V | V | V | V | V |
| 2020 Colacchio                  | Retrospective series | 29                 | Revision      | 61.4           | 47                     | 6, 10        | V | V | V | V | V | V | V | V |
| 2020 Civinini                   | Retrospective series | 37                 | Revision      | 63.7           | 61.2                   | 5            | V | V | V | V | V | V | V | V |
| 2020 Ait Mokhtar                | Retrospective series | 148                | Primary       | 78             | 38                     | 2            | V | V | V | V | V | V | V | V |
| 2020 Abdel                      | Retrospective series | 126                | Revision      | 66             | 43.2                   | 5            | V | V | V | V | V | V | V | V |
| 2019 Ukaj                       | Prospective series | 47                  | Primary       | 78.1           | 36                     | 2            | V | V | V | V | V | V | V | V |
| 2019 Tabori-jensen, Arch        | Retrospective series | 997                | Primary       | 80.5           | 64.8                   | 1, 11        | V | V | V | V | V | V | V | V |
| 2019 Schmidt-braekling           | Retrospective series | 77                 | Revision      | 68.5           | 63.6                   | 1, 4         | V | V | V | V | V | V | V | V |
| 2019 Nonne                      | Retrospective series | 60                 | Primary       | 87.6           | 28.3                   | 12           | V | V | V | V | V | V | V | V |
| 2019 Neil Wheeldon              | Retrospective series | 54                 | Revision      | 78             | 22.8                   | NR           | V | V | V | V | V | V | V | V |
| 2019 Nam                        | Prospective series | 43                  | Primary       | 52.6           | 24                     | 5            | V | V | V | V | V | V | V | V |
| 2019 Markel                     | Prospective series | 21                  | Primary       | 61.7           | 24                     | 5            | V | V | V | V | V | V | V | V |
| 2019 Li                         | Retrospective series | 94                 | Revision      | 63.6           | 37.8                   | 5            | V | V | V | V | V | V | V | V |
| 2019 Kreipke                    | Retrospective series | 2277                | Primary       | 75.5           | 35.9                   | 1, 11, 13    | V | V | V | V | V | V | V | V |
| 2019 Jones                      | Retrospective series | 151                | Primary       | 82             | 43.2                   | 6            | V | V | V | V | V | V | V | V |
| 2019 Jobory                     | Retrospective series | 4520               | Primary       | 77             | 25.2                   | 1, 11, 13    | V | V | V | V | V | V | V | V |
| 2019 Iorio                      | Retrospective series | 30                 | Primary       | 82             | 12                     | 2            | V | V | V | V | V | V | V | V |
| 2019 Huang                      | Retrospective series | 315                | Revision      | 65.8           | 39.6                   | 5            | V | V | V | V | V | V | V | V |
| 2019 Huang                      | Retrospective series | 107                | Recurrent dislocation | 65.8 | 39.6       | 5            | V | V | V | V | V | V | V | V |
| Author, Year       | Study design     | No. of THA procedure | Indications | Mean age (yrs) | Follow up duration (m) | Implant type | A | B | C | D | E | F | G | H |
|-------------------|------------------|----------------------|-------------|---------------|------------------------|--------------|---|---|---|---|---|---|---|---|
| 2019 Gaillard     | Retrospective    | 138                  | Primary     | 68            | 152.4                  | 11           | V | V | V | V | V | V | V | V |
| 2019 Fessy        | Retrospective    | 541                  | Primary     | 73.6          | 103.2                  | 3            | V | V | V | V | V | V | V | V |
| 2019 Fahad        | Retrospective    | 27                   | Primary     | 69.3          | 19                     | NR           | V | V | V | V | V | V | V | V |
| 2019 Dublin       | Retrospective    | 287                  | Primary     | 67.8          | 34.3                   | 6            | V | V | V | V | V | V | V | V |
| 2019 Dubin        | Retrospective    | 287                  | Primary     | 67.9          | 34.3                   | 5            | V | V | V | V | V | V | V | V |
| 2019 Dikmen       | Prospective      | 34                   | Revision    | 66.1          | 42.24                  | 13           | V | V | V | V | V | V | V | V |
| 2019 Cypres       | Retrospective    | 244                  | Primary     | 63.8          | 142.8                  | 13           | V | V | V | V | V | V | V | V |
| 2019 Chalmers     | Retrospective    | 24                   | Revision    | 63            | 48                     | 5            | V | V | V | V | V | V | V | V |
| 2019 Canton       | Retrospective    | 31                   | Primary     | 76.7          | 67.2                   | 1            | V | V | V | V | V | V | V | V |
| 2019 Boulat       | Retrospective    | 33                   | Primary     | 74            | 44                     | 3            | V | V | V | V | V | V | V | V |
| 2019 Bloemheuvel  | Retrospective    | 3038                 | Primary     | 70            | 36                     | 1, 2, 11, 13, 14 | V | V | V | V | V | V | V | V |
| 2019 Assi(J Arthroplasty) | Retrospective | 125                  | Primary     | 78.1          | 61.2                   | 1, 2         | V | V | V | V | V | V | V | V |
| 2019 Assi(Int Orthop) | Retrospective | 16                   | Revision    | 69.2          | 72.9                   | NR           | V | V | V | V | V | V | V | V |
| 2019 Addona       | Retrospective    | 229                  | Primary     | 62            | 70                     | 1, 2         | V | V | V | V | V | V | V | V |
| 2019 Addona       | Retrospective    | 107                  | Primary     | NR            | NR                     | 5; 15        | V | V | V | V | V | V | V | V |
| 2018 Tabori-Jensen| Retrospective    | 124                  | Primary     | 74.7          | 33.6                   | 11           | V | V | V | V | V | V | V | V |
| 2018 Stucinskas   | Retrospective    | 247                  | Revision    | 72            | 24                     | 1; 2         | V | V | V | V | V | V | V | V |
| 2018 Spaans       | Retrospective    | 102                  | Recurrent dislocation | 73.1          | 27.6                   | 1            | V | V | V | V | V | V | V | V |
| 2018 Rashed       | Prospective      | 32                   | Primary     | 66.4          | 12                     | 4            | V | V | V | V | V | V | V | V |
| 2018 Perrin       | Prospective      | 24                   | Revision    | 79.5          | 6                      | NR           | V | V | V | V | V | V | V | V |
| 2018 Ozden        | Retrospective    | 20                   | Revision    | 64.5          | 38.1                   | 13           | V | V | V | V | V | V | V | V |
| 2018 Marie-hardy  | Retrospective    | 16                   | Primary     | 69.6          | 29                     | 3            | V | V | V | V | V | V | V | V |
| 2018 Lange        | Retrospective    | 40                   | Recurrent dislocation | 64            | 36                     | 5; 6         | V | V | V | V | V | V | V | V |
| 2018 Kim          | Retrospective    | 84                   | Primary     | 73.1          | 21.7                   | 5            | V | V | V | V | V | V | V | V |
| 2018 Kavcic       | Retrospective    | 173                  | Primary     | 76.8          | 92.4                   | 1            | V | V | V | V | V | V | V | V |
| 2018 Kasparek     | Retrospective    | 11                   | Revision    | 64            | 31                     | 5; 6         | V | V | V | V | V | V | V | V |
| 2018 Hwang        | Prospective      | 167                  | Primary     | 72            | 22                     | 10           | V | V | V | V | V | V | V | V |
| Author, Year | Study design | No. of THA procedure | Indications | Mean age (yrs) | Follow up duration (m) | Implant type | A | B | C | D | E | F | G | H |
|-------------|--------------|----------------------|-------------|---------------|------------------------|--------------|---|---|---|---|---|---|---|---|
| 2018 Harwin | Retrospective series | 85 | Revision | 67 | 48 | 5 | V | V | V | V | V | V | V | V |
| 2018 Hartzler | Retrospective series | 126 | Revision | 66 | 40 | 5 | V | V | V | V | V | V | V | V |
| 2018 Diamond | Retrospective series | 60 | Revision | 65.5 | 38.6 | 5 | V | V | V | V | V | V | V | V |
| 2018 Chalmers | Retrospective series | 14 | Recurrent dislocation | 65 | 37 | 5 | V | V | V | V | V | V | V | V |
| 2018 Boukebous | Retrospective series | 98 | Primary | 77.8 | 25.9 | 16, 17 | V | V | V | V | V | V | V | V |
| 2018 Assi | Retrospective series | 30 | Primary | 54.9 | 51 | 1; 2; 19 | V | V | V | V | V | V | V | V |
| 2017 Viste | Retrospective series | 334 | Revision | NR | 84 | 3 | V | V | V | V | V | V | V | V |
| 2017 Tarasevicius | Retrospective series | 620 | Revision | 63.2 | 30 | 1; 2 | V | V | V | V | V | V | V | V |
| 2017 Sutter | Retrospective series | 64 | Revision | 59 | 38 | 5 | V | V | V | V | V | V | V | V |
| 2017 Rowan | Retrospective series | 136 | Primary | 48.5 | 38.4 | 5; 6 | V | V | V | V | V | V | V | V |
| 2017 Puch | Prospective series | 103 | Primary | 49.9 | 132 | 20 | V | V | V | V | V | V | V | V |
| 2017 Puch | Prospective series | 217 | Primary | 72.3 | 149 | 20 | V | V | V | V | V | V | V | V |
| 2017 Ochi | Retrospective series | 33 | Primary | 80 | 15.8 | 5 | V | V | V | V | V | V | V | V |
| 2017 Nam | Prospective series | 26 | Primary | 52.8 | 12 | 5 | V | V | V | V | V | V | V | V |
| 2017 Martz | Retrospective series | 25 | Primary | 44 | 129.8 | 3 | V | V | V | V | V | V | V | V |
| 2017 Lebeau | Retrospective series | 62 | Revision | 75.5 | 77 | 2 (1st-gen) | V | V | V | V | V | V | V | V |
| 2017 Hemigou | Retrospective series | 35 | Revision | 73 | 84 | 2, 21 | V | V | V | V | V | V | V | V |
| 2017 Henawy | Prospective series | 24 | Primary | 68 | 12 | 3 | V | V | V | V | V | V | V | V |
| 2017 Hamadaouche | Retrospective series | 51 | Revision | 71.4 | 60 | 8 | V | V | V | V | V | V | V | V |
| 2017 Graversen | Retrospective series | 20 | Primary | 83 | 12 | 1 | V | V | V | V | V | V | V | V |
| 2017 Gonzalez | Prospective series | 150 | Revision | 73 | 6 | 13; 22 | V | V | V | V | V | V | V | V |
| 2017 Ferreira | Retrospective series | 553 | Primary | 71.2 | 36 | 2 | V | V | V | V | V | V | V | V |
| 2017 Ferreira | Retrospective series | 83 | Primary | 81.7 | 36 | 2 | V | V | V | V | V | V | V | V |
| 2017 Epinette | Retrospective series | 321 | Primary | 48.1 | 32.4 | 5, 6 | V | V | V | V | V | V | V | V |
| 2017 Chalmers | Retrospective series | 16 | Revision | 75 | 36 | 5 | V | V | V | V | V | V | V | V |
| 2017 Batalier | Retrospective series | 302 | Primary | 73 | 14 | 2, 23 | V | V | V | V | V | V | V | V |
| 2016 Nich | Retrospective series | 45 | Primary | 86.7 | 23.8 | 6; 24 | V | V | V | V | V | V | V | V |
| 2016 Morin | Retrospective series | 40 | Primary | 19.2 | 60 | NR | V | V | V | V | V | V | V | V |
| 2016 Jauregui | Retrospective series | 60 | Revision | 57 | 30 | 5 | V | V | V | V | V | V | V | V |
Table 1 Characteristics of included studies (Continued)

| Author, Year     | Study design       | No. of THA procedure | Indications               | Mean age (yrs) | Follow up duration (m) | Implant type |
|------------------|--------------------|----------------------|---------------------------|----------------|------------------------|--------------|
| 2016 Homma       | Retrospective series | 60                   | Primary                   | 75.6           | 6                      | V V V V V V V V |
| 2016 Haughom     | Retrospective series | 24                   | Primary                   | 50.2           | 3                      | NR V V |
| 2016 Griffin     | Prospective series  | 10                   | Primary                   | >60            | 12                     | 3 V V V V V V V V |
| 2016 Chughtai    | Retrospective series | 410                  | Primary                   | 64             | 36                     | 5 V V V V V V V V |
| 2016 Carulli     | Retrospective series | 31                   | Recurrent dislocation     | 75.4           | 45.6                   | 1 V V V V V V V V |
| 2015 Wegrzyn     | Retrospective series | 994                  | Revision                  | 70             | 87.6                   | 11 V V V V V |
| 2015 Vigdorchik  | Retrospective series | 485                  | Primary                   | 66             | 24                     | 6 V V V V V V V V |
| 2015 Vermersch   | Prospective series  | 86                   | Primary                   | 72             | 27                     | 3 V V V V V V V V |
| 2015 van Heumen  | Retrospective series | 50                   | Recurrent dislocation     | 67             | 29                     | 1 V V V V V V V V |
| 2015 Snir        | Retrospective series | 18                   | Revision                  | 50.6           | 26.5                   | 5; 6; 10 V V V V V V V V |
| 2015 Simian      | Retrospective series | 74                   | Revision                  | 67.9           | 87.6                   | 17; 18; 25 V V V V V V V V V |
| 2015 Mohammed    | Retrospective series | 20                   | Primary                   | 70.8           | 22                     | NR V V V V V V V V |
| 2015 Mohammed    | Retrospective series | 24                   | Revision                  | 76.4           | 22                     | NR V V V V V V V V |
| 2015 Epinette    | Prospective series  | 143                  | Primary                   | 70.6           | 50                     | 6 V V V V V V V V |
| 2015 Bel         | Retrospective series | 18                   | Primary                   | 84             | 36                     | 3 V V V V V V V V |
| 2014 Wegrzyn     | Prospective series  | 61                   | Revision                  | 67             | 86                     | 11 V V V V V V V V V |
| 2014 Prudhon     | Prospective series  | 79                   | Revision                  | 62.5           | 24                     | 7 V V V V V V V V |
| 2014 Jakobsen    | Retrospective series | 56                   | Recurrent dislocation     | 72             | 44                     | 11 V V V V V V V V |
| 2014 Epinette    | Prospective series  | 437                  | Primary                   | 74.2           | 24                     | 6 V V V V V V V V |
| 2014 Caton       | Retrospective series | 105                  | Primary                   | 78             | 120                    | 2 V V V V V V |
| 2014 Bensen      | Retrospective series | 175                  | Primary                   | 75.2           | 21.7                   | 11 V V V V V V V V |
| 2013 Tarasevicius| Retrospective series | 41                   | Primary                   | 75             | 12                     | 1 V V V V V V V V |
| 2013 Saragaglia  | Retrospective series | 29                   | Recurrent dislocation     | 75.6           | 46                     | 1; 3; 20; 24 V V V V V V V V |
| 2013 Sanders     | Retrospective series | 10                   | Primary                   | 54             | 39                     | 1 V V V V V V V V |
| 2013 Prudhon     | Retrospective series | 105                  | Primary                   | 78             | 91                     | 2 V V V V V V V V |
| 2012 Vasukutty   | Retrospective series | 143                  | Revision                  | 77             | 42                     | NR V V V V V V V V |
| 2012 Pattyn      | Retrospective series | 36                   | Revision                  | 70             | 16                     | 26 V V V V V V V V |
| 2012 Hamadouche  | Retrospective series | 119                  | Primary                   | 67             | 72                     | 9 V V V V V V |
| 2012 Hailer      | Retrospective series | 228                  | Recurrent dislocation     | 75             | 24                     | 1 V V V V V V V V |

Pai et al. BMC Musculoskeletal Disorders (2021) 22:541 Page 7 of 28
outcome domains (n=21), mixed etiologies (n=12), 1st generation DM designs (n=10), cemented liner to cup (n=9), cadaveric or in vitro studies (n=3), studies not written in English (n=3). After exclusion, a total of 119 studies were included [41–115, 120–163] (Figure 1). Of these studies, 45 were case-control studies while 74 were case series. Since the objectives of this study were to validate the risk factors and modes of failures in the modern dual mobility implants, we extracted only the dual mobility group but not the control group from the 45 case-control studies.

Baseline characteristics
This study included 30016 patients who had undergone DM-THA for primary and revision THA procedures. The mean age was 71.9 years (range, 19.2 to 87.6) and 63.2% of the patients were female. Mean follow-up duration in overall, primary, revision and recurrent dislocation were 47.29 months (range, 6 to 87.6) and 63.2% of the patients were female. Mean age was 71.9 years (range, 19.2 to 87.6), and 35.23 months (range, 3 to 152.4), 40.86 months (range, 3 to 152.4), 61.82 months (range, 6 to 87.6), and 35.23 months (range, 24 to 55), respectively. DM-THA was used in 19819 primary THA procedures, 9411 revision THA procedures and 786 revision THA procedures for recurrent dislocation.

Aseptic loosening
A total of 105 studies, including 28980 DM-THA procedures, reported the rate of aseptic loosening. The pooled rate was 1.6% (95% CI 0.008 – 0.032). The aseptic loosening rate in primary THA, revision THA and revision THA for recurrent dislocation were 0.9%, 2.2% and 2.4%, respectively (Table 4, Figure S1). A multivariate regression analysis revealed that both revision THA for all causes (β=1.30, 95% CI 0.71 – 1.89), or for recurrent dislocation (β=1.18, 95% CI 0.26 – 2.10), carried a higher risk of aseptic loosening compared with a primary THA procedure (Table 5).

Septic loosening
A total of 105 studies, including 28980 DM-THA procedures, reported septic loosening rates. The pooled rate was 1.6% (95% CI 0.007 – 0.037). The septic loosening rate in primary THA, revision THA and revision THA procedure for recurrent dislocation were 0.8%, 2.3% and 2.5%, respectively (Table 4, Figure S2). A multivariate regression analysis showed that both revision THA for all causes (β=1.85, 95% CI 1.26 – 2.44) and for recurrent dislocation (β=1.40, 95% CI 0.45 – 2.36) were at a higher risk of septic loosening, compared with a primary THA procedure (Table 5).
| Criteria                                                                 | 2020 Nessler et al. | 2020 Laende et al. | 2020 Favreau et al. | 2020 Dublin (Arthroplasty Today) et al. | 2020 de l’Escalopier et al. | 2020 Colacchio et al. | 2020 Civinini et al. | 2020 Ait Mokhtar et al | 2019 Tabori-jensen et al. |
|------------------------------------------------------------------------|---------------------|--------------------|---------------------|----------------------------------------|----------------------------|---------------------|----------------------|----------------------|----------------------------|
| 1. Was the study question or objective clearly stated?                 | Y                   | Y                  | Y                   | Y                                      | Y                          | Y                   | Y                    | Y                    | Y                          |
| 2. Was the study population clearly and fully described, including a case definition? | Y                   | Y                  | Y                   | Y                                      | Y                          | Y                   | Y                    | Y                    | Y                          |
| 3. Were the cases consecutive?                                         | N                   | Y                  | N                   | N                                      | Y                          | N                   | N                    | Y                    | Y                          |
| 4. Were the subjects comparable?                                       | N                   | N                  | N                   | N                                      | N                          | N                   | N                    | N                    | N                          |
| 5. Was the intervention clearly described?                             | Y                   | Y                  | Y                   | Y                                      | Y                          | Y                   | Y                    | Y                    | Y                          |
| 6. Were the outcome measures clearly defined, valid, reliable and implemented consistently across all study participants? | Y                   | Y                  | Y                   | Y                                      | Y                          | Y                   | Y                    | Y                    | Y                          |
| 7. Was the length of follow-up adequate?                               | Y                   | Y                  | Y                   | Y                                      | Y                          | Y                   | Y                    | Y                    | Y                          |
| 8. Were the statistical methods well-described?                        | Y                   | Y                  | Y                   | Y                                      | Y                          | Y                   | Y                    | Y                    | Y                          |
| 9. Were the results well-described?                                    | Y                   | Y                  | Y                   | Y                                      | Y                          | Y                   | Y                    | Y                    | Y                          |
| Quality of the cohort study (score)                                   | 7                   | 8                  | 7                   | 7                                      | 8                          | 7                   | 7                    | 8                    | 7                          |

| Criteria                                                                 | 2019 Schmidtbraekling et al. | 2019 Neil Wheelton et al. | 2019 Nam et al. | 2019 Markel et al. | 2019 Jones et al. | 2019 Huang et al. | 2019 Gaillard et al. | 2019 Fessy et al. | 2019 Dikmen et al. | 2019 Cypres et al. | 2019 Chalmers et al. |
|------------------------------------------------------------------------|-----------------------------|---------------------------|----------------|-------------------|------------------|-------------------|---------------------|-------------------|------------------|--------------------|---------------------|
| 1. Was the study question or objective clearly stated?                 | Y                           | Y                         | Y               | Y                 | Y                | Y                 | Y                   | Y                 | Y                | Y                  | Y                   |
| 2. Was the study population clearly and fully described, including a case definition? | Y                           | Y                         | Y               | Y                 | Y                | Y                 | Y                   | Y                 | Y                | Y                  | Y                   |
| 3. Were the cases consecutive?                                         | Y                           | Y                         | N               | N                 | Y                | Y                 | Y                   | Y                 | Y                | Y                  | Y                   |
| 4. Were the subjects comparable?                                       | N                           | N                         | N               | N                 | N                | N                 | N                   | N                 | N                | N                  | N                   |
| 5. Was the intervention clearly described?                             | Y                           | Y                         | Y               | Y                 | Y                | Y                 | Y                   | Y                 | Y                | Y                  | Y                   |
| 6. Were the outcome measures clearly defined, valid, reliable and implemented consistently across all study participants? | Y                           | Y                         | Y               | Y                 | Y                | Y                 | Y                   | Y                 | Y                | Y                  | Y                   |
| 7. Was the length of follow-up                                       | Y                           | N                         | Y               | Y                 | Y                | Y                 | Y                   | Y                 | Y                | Y                  | Y                   |
| Criteria | 2020 Nessler et al. | 2020 Laende et al. | 2020 Favreau et al. | 2020 Dubin (Arthroplasty Today) et al. | 2020 de l’Escalopier et al. | 2020 Colacchio et al. | 2020 Civinini et al. | 2020 Ait Mokhtar et al | 2019 Tabori-Jensen et al. |
|----------|-------------------|-------------------|-------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------------|--------------------------------|
| 1. Was the study question or objective clearly stated? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 2. Was the study population clearly and fully described, including a case definition? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 3. Were the cases consecutive? | N | N | N | N | Y | N | Y | N | N |
| 4. Were the subjects comparable? | N | N | N | N | N | N | N | N | N |
| 5. Was the intervention clearly described? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 6. Were the outcome measures clearly defined, valid, reliable and implemented consistently across all study participants? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 7. Was the length of follow-up adequate? | Y | Y | Y | Y | N | N | Y | Y | Y |
| 8. Were the statistical methods well-described? | Y | Y | Y | Y | N | Y | N | Y | Y |
| 9. Were the results well-described? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Quality of the cohort study (score) | 7 | 7 | 7 | 7 | 6 | 6 | 8 | 7 | 7 |
| Criteria | 2018 Hwang et al. | 2018 Diamond et al. | 2018 Chalmers et al. | 2018 Assi (J Arthroplasty) et al. | 2017 Viste et al. | 2017 Sutter et al. | 2017 Puch et al. | 2017 Nair et al. | 2017 Martz et al. | 2017 Lebeau et al. | 2017 Henawy et al. | 2017 Hamadouche et al. |
| 1. Was the study question or objective clearly stated? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 2. Was the study population clearly and fully described, including a case definition? | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Criteria                                                                 | 2020 Nessler et al. | 2020 Laende et al. | 2020 Favreau et al. | 2020 Dublin (Arthroplasty Today) et al. | 2020 de l’Escautopier et al. | 2020 Colacchio et al. | 2020 Civinini et al. | 2020 Ait Mokhtar et al. | 2019 Tabori-Jensen et al. |
|------------------------------------------------------------------------|---------------------|--------------------|---------------------|----------------------------------------|-------------------------------|---------------------|------------------------|------------------------|---------------------------|
| 3. Were the cases consecutive?                                         | N                   | Y                  | N                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                         |
| 4. Were the subjects comparable?                                      | N                   | N                  | N                   | N                                      | N                             | N                   | N                      | N                      | N                         |
| 5. Was the intervention clearly described?                            | Y                   | Y                  | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                         |
| 6. Were the outcome measures clearly defined, valid, reliable and implemented consistently across all study participants? | Y                   | Y                  | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                         |
| 7. Was the length of follow-up adequate?                              | N                   | Y                  | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                         |
| 8. Were the statistical methods well-described?                        | Y                   | Y                  | N                   | Y                                      | Y                             | Y                   | Y                      | Y                      | N                         |
| 9. Were the results well-described?                                   | Y                   | Y                  | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                         |
| Quality of the cohort study (score)                                   | 6                   | 8                  | 6                   | 7                                      | 8                             | 8                   | 8                      | 6                      | 7                         |

| Criteria                                                                 | 2017 Graversen et al. | 2017 Ferreira et al. | 2017 Epinette et al. | 2016 Nich et al. | 2016 Morin et al. | 2016 Chughtai et al. | 2016 Carulli et al. | 2015 Wegrzyn et al. | 2015 Vigdorchik et al. | 2015 Vernersch et al. | 2015 van Heumen et al. |
|------------------------------------------------------------------------|---------------------|---------------------|---------------------|----------------|-------------------|----------------------|---------------------|----------------------|------------------------|------------------------|------------------------|
| 1. Was the study question or objective clearly stated?                 | Y                   | Y                   | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                      | Y                      |
| 2. Was the study population clearly and fully described, including a case definition? | Y                   | Y                   | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                      | Y                      |
| 3. Were the cases consecutive?                                         | N                   | N                   | N                   | N                                      | N                             | N                   | N                      | N                      | N                      | Y                      |
| 4. Were the subjects comparable?                                      | N                   | N                   | N                   | N                                      | N                             | N                   | N                      | N                      | N                      | N                      |
| 5. Was the intervention clearly described?                            | Y                   | Y                   | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                      | Y                      |
| 6. Were the outcome measures clearly defined, valid, reliable and implemented consistently across all study participants? | Y                   | Y                   | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                      | Y                      |
| 7. Was the length of follow-up adequate?                              | N                   | Y                   | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                      | Y                      |
| 8. Were the statistical methods well-described?                        | Y                   | Y                   | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                      | Y                      |
| 9. Were the results well-described?                                   | Y                   | Y                   | Y                   | Y                                      | Y                             | Y                   | Y                      | Y                      | Y                      | Y                      |
| Criteria | 2020 Nessler et al. | 2020 Laende et al. | 2020 Favreau et al. | 2020 Dubin (Arthroplasty Today) et al. | 2020 de l'Escalopier et al. | 2020 Colacchio et al. | 2020 Civinini et al. | 2020 Ait Mokhtar et al. | 2019 Taborijensen et al. |
|----------|-------------------|-------------------|-------------------|--------------------------------------|------------------------|-------------------|-------------------|-------------------|-------------------|
| Quality of the cohort study (score) | 6 | 7 | 7 | 7 | 7 | 6 | 6 | 7 | 8 |
| Criteria 2015 Snir et al. | 2015 Simian et al. | 2015 Mohammed et al. | 2014 Wegrzyn et al. | 2014 Prudhon et al. | 2013 Saragaglia et al. | 2013 Sanders et al. | 2013 Prudhon et al. | 2012 Vasukutty et al. | 2012 Pattyn et al. |
| 1. Was the study question or objective clearly stated? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 2. Was the study population clearly and fully described, including a case definition? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 3. Were the cases consecutive? | Y | N | N | N | N | Y | Y | N | Y |
| 4. Were the subjects comparable? | N | N | N | N | N | N | N | N | N |
| 5. Was the intervention clearly described? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 6. Were the outcome measures clearly defined, valid, reliable and implemented consistently across all study participants? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 7. Was the length of follow-up adequate? | N | Y | N | Y | Y | Y | Y | Y | N |
| 8. Were the statistical methods well-described? | N | Y | N | Y | Y | Y | N | Y | N |
| 9. Were the results well-described? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Quality of the cohort study (score) | 6 | 7 | 5 | 7 | 8 | 8 | 6 | 8 | 5 |
| Criteria 2012 Hamadouche et al. | 2012 Hailler et al. | 2012 Civinini et al. | 2012 Adam et al. | 2011 Schneider et al. | 2010 Hamadouche et al. | 2009 Guyen et al. | 2008 Langlais et al. | 2008 Bauchu et al. |
| 1. Was the study question or objective clearly stated? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 2. Was the study population clearly and fully described, including a case definition? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 3. Were the cases consecutive? | N | N | N | N | N | N | N | Y | Y |
| 4. Were the subjects comparable? | N | N | N | N | N | N | N | N | N |
| 5. Was the intervention clearly described? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| 6. Were the outcome measures clearly defined, valid, reliable and implemented consistently across all study participants? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Criteria | 2020 Nessler et al. | 2020 Laende et al. | 2020 Favreau et al. | 2020 Dubin (Arthroplasty Today) et al. | 2020 de l’Escalopier et al. | 2020 Colacchio et al. | 2020 Civinini et al. | 2020 Ait Mokhtar et al. | 2019 Tabori-jensen et al. |
|----------|------------------|------------------|------------------|--------------------------------|------------------|------------------|------------------|------------------|------------------|
| 7. Was the length of follow-up adequate? | Y | Y | Y | N | Y | Y | Y | Y | Y |
| 8. Were the statistical methods well-described? | Y | Y | Y | Y | Y | Y | Y | Y | N |
| 9. Were the results well-described? | Y | Y | Y | Y | Y | Y | Y | Y | Y |
| Quality of the cohort study (score) | 7 | 7 | 7 | 6 | 7 | 7 | 7 | 7 | 7 |

Y= Yes, N= No; The maximum possible score on this scale is 9. “Good” was defined as a total score of 7-9; “fair” as a score 4-6, and “poor” as a score of less than 4.
## Table 3: Study assessment based on quality assessment tool for case control studies

| Criteria                                                                 | 2020 Tabori-jensen et al. | 2020 Schmidt et al. | 2020 Rashed et al. | 2020 Klemt et al. | 2020 Hoggett et al. | 2020 Dubin et al. | 2020 Abdel et al. |
|-------------------------------------------------------------------------|---------------------------|---------------------|-------------------|-------------------|-------------------|------------------|------------------|
| 1. Was the research question or objective in this paper clearly stated and appropriate? | Y                         | Y                   | Y                 | Y                 | Y                 | Y                | Y                |
| 2. Was the study population clearly specified and defined?              | Y                         | Y                   | Y                 | Y                 | Y                 | Y                | Y                |
| 3. Did the authors include a sample size justification?                 | Y                         | N                   | Y                 | Y                 | N                 | N                | N                |
| 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? | Y                         | Y                   | Y                 | N                 | Y                 | Y                | Y                |
| 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? | Y                         | Y                   | Y                 | Y                 | Y                 | Y                | Y                |
| 6. Were the cases clearly defined and differentiated from controls?      | Y                         | Y                   | Y                 | Y                 | Y                 | Y                | Y                |
| 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? | Y                         | N                   | Y                 | N                 | N                 | N                | N                |
| 8. Was there use of concurrent controls?                                | NR                        | NR                  | NR                | NR                | NR                | NR               | NR               |
| 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? | Y                         | Y                   | Y                 | Y                 | Y                 | Y                | Y                |
| 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? | Y                         | Y                   | Y                 | N                 | N                 | Y                | Y                |
| 11. Were the assessors of exposure/risk blinded to the case or control status of participants? | Y                         | N                   | N                 | N                 | N                 | N                | N                |
| 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis? | N                         | N                   | N                 | N                 | N                 | N                | N                |

| Quality of the cohort study (score)                                   | 10                        | 7                   | 9                 | 6                 | 6                 | 7                | 7                |
|-----------------------------------------------------------------------|---------------------------|---------------------|-------------------|-------------------|-------------------|------------------|------------------|
| Criteria                                                             | 2019 Ukaj et al.          | 2019 Nonne et al.   | 2019 Li et al.    | 2019 Kreipke et al. | 2019 Jobory et al. | 2019 Iorio et al. | 2019 Fahad et al. | 2019 Dubin et al. |
| 1. Was the research question or objective in this paper clearly stated and appropriate? | Y                         | Y                   | Y                 | Y                 | Y                 | Y                | Y                | Y                |
| 2. Was the study population clearly specified and defined?            | Y                         | Y                   | Y                 | Y                 | Y                 | Y                | Y                | Y                |
| 3. Did the authors include a sample size justification?               | Y                         | N                   | Y                 | N                 | N                 | N                | N                | N                |
| 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? | Y                         | Y                   | Y                 | N                 | N                 | Y                | Y                | Y                |
| 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently | Y                         | Y                   | Y                 | Y                 | Y                 | Y                | Y                | Y                |
| Criteria | 2020 Tabori-jensen et al. | 2020 Schmidt et al. | 2020 Rashed et al. | 2020 Klement et al. | 2020 Hogget et al. | 2020 Dubin et al. | 2020 Abdel et al. |
|----------|--------------------------|---------------------|-------------------|-------------------|------------------|-----------------|------------------|
| across all study participants? | Y | Y | Y | Y | Y | Y | Y |
| 6. Were the cases clearly defined and differentiated from controls? | Y | N | N | N | N | Y | N |
| 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? | N | N | N | N | N | N | N |
| 8. Was there use of concurrent controls? | NR | NR | NR | NR | NR | NR | NR |
| 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? | Y | Y | Y | Y | Y | Y | Y |
| 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? | Y | Y | Y | N | N | Y | Y |
| 11. Were the assessors of exposure/risk blinded to the case or control status of participants? | Y | N | N | N | N | N | N |
| 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis? | N | N | N | N | N | N | N |
| Quality of the cohort study (score) | 10 | 7 | 8 | 5 | 5 | 8 | 7 | 7 |
| Criteria | 2019 Bloemheuvel, van Steenbergen et al. | 2019 Bloemheuvel, Steenbergen et al. | 2019 Assi (Int Orthop) et al. | 2018 Stucinskas et al. | 2018 Tabori-Jensen et al. | 2018 Spaans et al. | 2018 Perrin et al. | 2018 Kim et al. |
| 1. Was the research question or objective in this paper clearly stated and appropriate? | Y | Y | Y | Y | Y | Y | Y | Y |
| 2. Was the study population clearly specified and defined? | Y | Y | Y | Y | Y | Y | Y | Y |
| 3. Did the authors include a sample size justification? | N | N | N | N | N | N | Y | N |
| 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? | N | N | Y | Y | Y | Y | Y | Y |
| 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? | Y | Y | Y | Y | Y | Y | Y | Y |
| 6. Were the cases clearly defined and differentiated from controls? | Y | Y | Y | Y | Y | Y | Y | Y |
| 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? | N | N | N | N | N | N | N | N |
| 8. Was there use of concurrent controls? | NR | NR | NR | NR | NR | NR | NR | NR |
| 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that | Y | Y | Y | Y | Y | Y | Y | Y |
Table 3  Study assessment based on quality assessment tool for case control studies (Continued)

| Criteria                                                                 | 2020 Taborijensen et al. | 2020 Schmidt et al. | 2020 Rashed et al. | 2020 Klemt et al. | 2020 Hoggett et al. | 2020 Dubin et al. | 2020 Abdel et al. |
|-------------------------------------------------------------------------|--------------------------|---------------------|--------------------|-------------------|--------------------|-------------------|------------------|
| defined a participant as a case?                                        | N                        | N                   | Y                  | Y                 | Y                  | Y                 | Y                |
| 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? | N                        | N                   | N                  | N                 | N                  | N                 | N                |
| 11. Were the assessors of exposure/risk blinded to the case or control status of participants? | N                        | N                   | N                  | N                 | N                  | N                 | N                |
| 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis? | N                        | N                   | N                  | N                 | N                  | N                 | N                |
| Quality of the cohort study (score)                                     | 5                        | 5                   | 7                  | 7                 | 7                  | 7                 | 8                |
| 1. Was the research question or objective in this paper clearly stated and appropriate? | Y                        | Y                   | Y                  | Y                 | Y                  | Y                 | Y                |
| 2. Was the study population clearly specified and defined?              | Y                        | Y                   | Y                  | Y                 | Y                  | Y                 | Y                |
| 3. Did the authors include a sample size justification?                 | N                        | N                   | Y                  | N                 | N                  | N                 | N                |
| 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? | Y                        | Y                   | Y                  | N                 | Y                  | Y                 | Y                |
| 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? | Y                        | Y                   | Y                  | Y                 | Y                  | Y                 | Y                |
| 6. Were the cases clearly defined and differentiated from controls?     | Y                        | Y                   | Y                  | Y                 | Y                  | Y                 | Y                |
| 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? | N                        | N                   | N                  | N                 | N                  | Y                 | N                |
| 8. Was there use of concurrent controls?                               | NR                       | NR                  | NR                 | NR                | NR                 | NR                | NR               |
| 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? | Y                        | Y                   | Y                  | Y                 | Y                  | Y                 | Y                |
| 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? | Y                        | Y                   | Y                  | N                 | Y                  | Y                 | Y                |
| 11. Were the assessors of exposure/risk blinded to the case or control status of participants? | N                        | N                   | N                  | N                 | N                  | N                 | N                |
| 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis? | N                        | N                   | N                  | N                 | N                  | N                 | N                |
| Criteria                                                                 | 2020 Tabori-Jensen et al. | 2020 Schmidt et al. | 2020 Rashed et al. | 2020 Klemt et al. | 2020 Hoggett et al. | 2020 Dubin et al. | 2020 Abdel et al. |
|------------------------------------------------------------------------|----------------------------|---------------------|--------------------|-------------------|--------------------|-------------------|-------------------|
| Quality of the cohort study (score)                                    | 7                          | 7                   | 8                  | 6                 | 7                  | 8                 | 7                 |
| 1. Was the research question or objective in this paper clearly stated and appropriate? | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 | Y                 |
| 2. Was the study population clearly specified and defined?             | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 | Y                 |
| 3. Did the authors include a sample size justification?                | N                          | N                   | N                  | N                 | Y                  | N                 | N                 |
| 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 | Y                 |
| 5. Were the definitions, inclusion and exclusion criteria, algorithms or processes used to identify or select cases and controls valid, reliable, and implemented consistently across all study participants? | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 | Y                 |
| 6. Were the cases clearly defined and differentiated from controls?    | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 | Y                 |
| 7. If less than 100 percent of eligible cases and/or controls were selected for the study, were the cases and/or controls randomly selected from those eligible? | N                          | N                   | N                  | N                 | N                  | N                 | Y                 |
| 8. Was there use of concurrent controls?                               | NR                         | NR                  | NR                 | NR                | NR                 | NR                | NR                |
| 9. Were the investigators able to confirm that the exposure/risk occurred prior to the development of the condition or event that defined a participant as a case? | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 | Y                 |
| 10. Were the measures of exposure/risk clearly defined, valid, reliable, and implemented consistently (including the same time period) across all study participants? | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 | Y                 |
| 11. Were the assessors of exposure/risk blinded to the case or control status of participants? | N                          | N                   | N                  | N                 | N                  | N                 | N                 |
| 12. Were key potential confounding variables measured and adjusted statistically in the analyses? If matching was used, did the investigators account for matching during study analysis? | N                          | Y                   | N                  | N                 | N                  | N                 | N                 |
| Quality of the cohort study (score)                                    | 7                          | 8                   | 7                  | 8                 | 9                  | 9                 | 7                 |
| Criteria                                                                 | 2014 Epinette et al.       | 2014 Caton et al.   | 2014 Bensen et al. | 2013 Tarasevicius et al. | 2011 Bouchet et al. | 2010 Tarasevicius et al. |
| 1. Was the research question or objective in this paper clearly stated and appropriate? | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 |
| 2. Was the study population clearly specified and defined?             | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 |
| 3. Did the authors include a sample size justification?                | N                          | N                   | N                  | Y                 | N                  | N                 |
| 4. Were controls selected or recruited from the same or similar population that gave rise to the cases (including the same timeframe)? | Y                          | Y                   | Y                  | Y                 | Y                  | Y                 |
Extra-articular dislocation

A total of 113 studies, including 20447 DM-THA procedures, presented the extra-articular dislocation rate. The pooled rate was 1.2% (95% CI 0.006 – 0.025). The extra-articular dislocation rate in primary THA, revision THA and revision THA for recurrent dislocation were 0.6%, 1.3% and 2.5%, respectively (Table 4, Figure S3). Compared with a primary THA procedure, risk of dislocation was higher after revision THA procedures (β=1.02, 95% CI 0.30 – 1.73) (Table 5).

Intra-prosthetic dislocation

A total of 113 studies, including 20447 DM-THA procedures, reported the intra-prosthetic dislocation rate. The overall rate was 1.0% (95% CI 0.007 – 0.015). The intra-prosthetic dislocation rate in primary THA, revision THA and revision THA for recurrent dislocation were 0.8%, 1.0% and 1.6%, respectively (Table 4, Figure S4). None of the factors including age, female sex, posterolateral approach, BMI or indication have led to intra-prosthetic dislocation (Table 5).

Periprosthetic fracture

A total of 100 studies, including 27731 DM-THA procedures, recorded the periprosthetic fracture rate. The pooled rate was 0.9% (95% CI 0.008 – 0.011). The periprosthetic fracture rates in primary THA, revision THA and revision THA for recurrent dislocation were 0.9%, 0.9% and 1.3%, respectively (Table 4, Figure S5). Revision THA procedure for all causes (β=0.93, 95% CI 0.23 – 1.62) was a risk factor for periprosthetic fracture (Table 5).

Overall implant failure

A total of 105 studies, including 27873 DM-THA procedures, recorded the implant failure rate. The pooled rate was 4.2% (95% CI 0.021 – 0.081) at a mean follow-up of 45.8 months. The implant failure rates in primary THA, revision THA and revision THA for recurrent dislocation were 2.3%, 5.5% and 6.0%, respectively (Table 4, Figure S6). Younger age (β=-0.04, 95% CI -0.07 – -0.02), female sex (β=3.34, 95% CI 0.91 – 5.78), revision THA procedure for all causes (β=1.48, 95% CI 0.93 – 2.03)
and for recurrent dislocation ($\beta=1.08$, 95% CI 0.24 – 1.92) were risk factors for implant failures (Table 5).

**Functional outcome**

We included 49 (N= 7086) and 21 (N= 2764) studies that evaluated the functional outcome using Harris hip score and Merle d’Aubigné score. The pooled Harris hip score and Merle d’Aubigné score were 84.87 (95% CI 78.99 – 90.76) and 16.36 (95% CI 15.20 – 17.53), respectively (Table 4, Figure S7, S8). Revision THA procedure for all causes ($\beta=-9.44$, 95% CI -15.17 – -3.72) and female sex ($\beta=-4.10$, 95% CI -8.17 – -0.03) were associated with lower functional scores. (Table 5).

**Discussion**

In this meta-analysis, we included 119 studies with 30016 primary and revision THA procedures using the modern DM design. At a mean follow-up of 47.3 months, the overall failure rate of modern dual mobility design was 4.2%. The most common failure modes include aseptic loosening (primary: 0.9%, revision for all causes: 2.2%, revision for recurrent dislocation: 2.4%), septic loosening (primary: 0.8%, revision for all causes: 2.3%, revision for recurrent dislocation: 2.5%), extra-articular dislocation (primary: 0.6%, revision for all causes: 1.3%, revision for recurrent dislocation: 2.5%), intra-prosthetic dislocation (primary: 0.8%, revision for all causes: 1.0%, revision for recurrent dislocation: 1.6%) and periprosthetic fracture (primary: 0.9%, revision for all causes: 0.9%, revision for recurrent dislocation: 1.3%). The multi-regression analysis revealed that revision THA procedures were associated with a higher risk of aseptic loosening, septic loosening, extra-articular dislocation, periprosthetic fracture, overall implant failure and lower Harris Hip scores. Interestingly, several risk factors that were identified for THA dislocation such as advanced age, female sex, posterolateral approach and increased BMI were not risk factors for extra-articular dislocation. On the other hand, younger and female patients were associated with higher risk of implant failure. In terms of functional outcome, the patients were satisfied with their postoperative function based on the improved Harris hip score and Merle d’Aubigné score.

Dislocation is one of the common causes of THA implant failure and can be caused by many factors [8]. In current literature, the known risk factors include advanced age, female patients [9, 10], obesity [11, 12], previous hip surgeries [13], posterolateral surgical approach [14, 15], THA for acute fractures, patients with neurological diseases [16], and patients with abductor weakness [17, 18]. The dual mobility design increases femoral head-to-neck ratio and jump distance to improve stability [20–23]. Therefore, we can anticipate decreased dislocation rates for the DM design in primary and revision

| Table 4 Pooled event rate and clinical performance stratified by indications |
|---------------------------------|-----------------|-----------------|
|                                | Rate or Mean Value | 95% CI          |
| Aseptic loosening              |                  |                 |
| Primary THA                    | 0.009            | 0.007-0.012     |
| Revision THA                   | 0.022            | 0.016-0.030     |
| Recurrent dislocation          | 0.024            | 0.013-0.045     |
| Overall                        | 0.016            | 0.008-0.032     |
| Septic loosening               |                  |                 |
| Primary THA                    | 0.008            | 0.006-0.011     |
| Revision THA                   | 0.023            | 0.017-0.032     |
| Recurrent dislocation          | 0.025            | 0.013-0.049     |
| Overall                        | 0.016            | 0.007-0.037     |
| Extra-articular dislocation    |                  |                 |
| Primary THA                    | 0.006            | 0.005-0.008     |
| Revision THA                   | 0.013            | 0.009-0.017     |
| Recurrent dislocation          | 0.025            | 0.014-0.043     |
| Overall                        | 0.012            | 0.006-0.025     |
| Intra-prosthetic dislocation   |                  |                 |
| Primary THA                    | 0.008            | 0.006-0.010     |
| Revision THA                   | 0.010            | 0.007-0.015     |
| Recurrent dislocation          | 0.016            | 0.008-0.031     |
| Overall                        | 0.010            | 0.007-0.015     |
| Periprosthetic fracture        |                  |                 |
| Primary THA                    | 0.009            | 0.007-0.011     |
| Revision THA                   | 0.009            | 0.006-0.012     |
| Recurrent dislocation          | 0.013            | 0.006-0.025     |
| Overall                        | 0.009            | 0.008-0.011     |
| Implant failure                |                  |                 |
| Primary THA                    | 0.023            | 0.018-0.030     |
| Revision THA                   | 0.055            | 0.042-0.073     |
| Recurrent dislocation          | 0.060            | 0.034-0.103     |
| Overall                        | 0.042            | 0.021-0.081     |
| Harris Hip score               |                  |                 |
| Primary THA                    | 89.47            | 87.62-91.33     |
| Revision THA                   | 81.89            | 78.96-84.83     |
| Recurrent dislocation          | 82.65            | 77.41-87.89     |
| Overall                        | 84.87            | 78.99-90.76     |
| Merle d’Aubigné score          |                  |                 |
| Primary THA                    | 17.08            | 16.85-17.30     |
| Revision THA                   | 15.45            | 15.07-15.83     |
| Recurrent dislocation          | 16.57            | 15.85-17.28     |
| Overall                        | 16.36            | 15.20-17.53     |

THA: total hip arthroplasty.
Table 5 Multivariate linear regression analysis

| Independent Variable | $\beta$-Coefficient | 95% Confidence Interval | P Value |
|----------------------|---------------------|-------------------------|---------|
| Aseptic loosening     |                     |                         |         |
| Age                  | -0.02               | -0.05 – 0.01            | 0.269   |
| Female Sex           | 0.55                | -2.08 – 3.17            | 0.683   |
| Posterolateral approach (ref to others) | 0.18 | -0.59 – 0.94 | 0.654 |
| BMI                  | -0.07               | -0.19 – 0.06            | 0.302   |
| Indication (ref to primary THA) | | | |
| Revision THA         | 1.30                | 0.71 – 1.89             | <0.001  |
| Recurrent dislocation | 1.18               | 0.26 – 2.10             | 0.012   |
| Septic loosening     |                     |                         |         |
| Age                  | -0.02               | -0.05 – 0.01            | 0.226   |
| Female Sex           | 1.39                | -1.54 – 4.32            | 0.353   |
| Posterolateral approach (ref to others) | 0.34 | -0.42 – 1.10 | 0.384 |
| BMI                  | -0.09               | -0.20 – 0.02            | 0.125   |
| Indication (ref to primary THA) | | | |
| Revision THA         | 1.85                | 1.26 – 2.44             | <0.001  |
| Recurrent dislocation | 1.40               | 0.45 – 2.36             | 0.004   |
| Extra-articular dislocation | | | |
| Age                  | 0.01                | -0.03 – 0.05            | 0.741   |
| Female Sex           | 1.18                | -1.82 – 4.18            | 0.440   |
| Posterolateral approach (ref to others) | -0.39 | -1.20 – 0.41 | 0.338 |
| BMI                  | -0.10               | -0.24 – 0.03            | 0.126   |
| Indication (ref to primary THA) | | | |
| Revision THA         | 1.02                | 0.30 – 1.73             | 0.006   |
| Recurrent dislocation | 0.78               | -0.49 – 2.04            | 0.230   |
| Intra-prosthetic dislocation | | | |
| Age                  | 0.00                | -0.05 – 0.04            | 0.829   |
| Female Sex           | 1.30                | -2.04 – 4.64            | 0.444   |
| Posterolateral approach (ref to others) | -0.31 | -1.19 – 0.56 | 0.482 |
| BMI                  | -0.05               | -0.18 – 0.08            | 0.473   |
| Indication (ref to primary THA) | | | |
| Revision THA         | 0.52                | -0.24 – 1.28            | 0.180   |
| Recurrent dislocation | 0.88               | -0.19 – 1.94            | 0.107   |
| Periprosthetic fracture | | | |
| Age                  | -0.02               | -0.06 – 0.02            | 0.340   |
| Female Sex           | 0.81                | -2.47 – 4.08            | 0.629   |
| Posterolateral approach (ref to others) | 0.21 | -0.70 – 1.12 | 0.651 |
| BMI                  | -0.07               | -0.22 – 0.08            | 0.364   |
| Indication (ref to primary THA) | | | |
| Revision THA         | 0.93                | 0.23 – 1.62             | 0.009   |
| Recurrent dislocation | 0.42               | -0.93 – 1.77            | 0.542   |
| Implant failure      |                     |                         |         |
| Age                  | -0.04               | -0.07 – 0.02            | 0.002   |
| Female Sex           | 3.34                | 0.91 – 5.78             | 0.007   |
| Posterolateral approach (ref to others) | 0.34 | -0.32 – 1.01 | 0.309 |
THA. Even after revision THA due to recurrent instability, the dislocation rate was only 2.5%, which was much lower than the reported dislocation rate after primary THAs and revision THAs, which ranged from 0.3% to 10% [2–4] and 5% to 30% [5–7], respectively. In addition, a multivariate analysis revealed that older age, female patients, posterolateral approach and BMI were not risk factors for dislocation after DM-THA. Based on the difference in risk factors for dislocations, we can assume that the DM design can effectively overcome some of the shortcomings of previous THA designs. Nevertheless, optimization of component position and restoration of soft tissue tension are paramount to prevent dislocation in both primary and revision THA procedures.

Despite these improvements, there are still some concerns with the DM design, including increased wear of the acetabular liner [164], increased risk of aseptic loosening [30] and intra-prosthetic dislocation [30].

The two-articulation design creates two surfaces for plastic deformation and wear, which theoretically leads to a higher wear rate than fixed-bearing THA. The inner, small articulation dominates the majority of movement and follows the Charnley’s low-friction principle with a small-diameter head to reduce wear [20]. The motion between the outer shell and acetabular component occurs in extreme angle when femoral neck abuts the PE liner and creates a homogenous wear over the liner [40]. Using plain radiographs or implant retrieval analysis, several studies aimed to assess the volumetric difference in wearing of DM articulations and fixed-bearing THA [165–172]. Interestingly, the wear rate of ultra-high molecular weight polyethylene (UHMWPE) bearing in the 1st generation DM cup was less than 40 mm³/year, which was similar to wear rate of UHMWPE in fixed-bearing THAs (30–80 mm³/year at 15 to 21 year follow up) [165–169]. In vitro simulation study for modern generation DM cup, using highly cross-linked polyethylene (HXLPE), reported lower wear rate in DM cup compared to fixed-bearing THA (1.2 vs. 2.7 mm³/million cycles, respectively) [170]. In another study performed by Laende et al., the wear rate of modern generation DM cups with HXLPE at 3 years follow-up was 0.02 mm/year in DM cup, which was similar to non-dual mobility constructs (0.00 to 0.06 mm/year) [69, 171]. In contrast, Deckard et al. recorded the wear rate was two times higher for modern-generation DM cup with HXLPE than the fixed-bearing THA (0.27 mm/year and 0.11 mm/year, respectively) [172]. The in vitro simulation or retrieval studies have validated reasonable wear rates of DM articulation using either UHMWPE or HXLPE [165–170]. The results from studies using plain radiographs to estimate the wear rate were controversial, which is considered less accurate than the retrieval or simulation studies [171, 172].

| Table 5 Multivariate linear regression analysis (Continued) |
|---------------------------------|---------------------------------|---------------------------------|
| Independent Variable            | β-Coefficient                   | 95% Confidence Interval          | P Value |
| BMI                             | -0.06                           | -0.16 – 0.05                     | 0.273   |
| Indication (ref to primary THA) |                                 |                                 |        |
| Revision THA                    | 1.48                            | 0.93 – 2.03                      | <0.001  |
| Recurrent dislocation           | 1.08                            | 0.24 – 1.92                      | 0.012   |
| Harris Hip score                |                                 |                                 |        |
| Age                             | -0.01                           | -0.34 – 0.32                     | 0.964   |
| Female Sex                      | 3.66                            | -15.82 – 23.15                   | 0.713   |
| Posterolateral approach (ref to others) | -1.71                         | -8.11 – 4.69                     | 0.601   |
| BMI                             | 0.58                            | -0.48 – 1.64                     | 0.285   |
| Indication (ref to primary THA) |                                 |                                 |        |
| Revision THA                    | -9.44                           | -15.17 – -3.72                   | 0.001   |
| Recurrent dislocation           | -6.81                           | -15.42 – 1.80                    | 0.121   |
| Merle d’Aubigné score           |                                 |                                 |        |
| Age                             | 0.03                            | -0.03 – 0.09                     | 0.378   |
| Female Sex                      | -4.10                           | -8.17 – -0.03                    | 0.049   |
| Posterolateral approach (ref to others) | 0.23                          | -0.64 – 1.11                     | 0.600   |
| BMI                             | 0.14                            | -0.03 – 0.31                     | 0.109   |
| Indication (ref to primary THA) |                                 |                                 |        |
| Revision THA                    | -0.38                           | -1.45 – 0.69                     | 0.487   |
| Recurrent dislocation           | -0.37                           | -1.81 – 1.07                     | 0.617   |

BMI: body mass index; ref: reference; THA: total hip arthroplasty
evidence regarding the increased PE wear of modern DM articulation.

The non-porous alumina-coated surface, tripod anchoring system of acetabular component and polyethylene wear have been associated with a higher aseptic loosening rate in the first-generation DM implants [24, 29, 31]. Several changes have been made in modern dual mobility designs, including (1) to replace UHMWPE with HXLPE to reduce wear [33, 34]; (2) to add bevelled edges (or chamfer) in polyethylene (PE) inserts to lower femoral neck impingement and wear [32]; (3) press-fit fixation by bilayer coating of porous titanium and hydroxyapatite to enhance osseointegration on the outer surface [31]; (4) modular metal liner design to facilitate supplementary screw fixation. The long-term overall survival and aseptic loosening rate of the primary THAs using 1st generation DM implants were 85-95.4% and 3-8.3%, respectively [24–28]. In this study, the primary THAs using modern generations DM implants are associated with a better overall survival (97.7%) and a lower aseptic loosening rate (0.9%). This pooled aseptic loosening rate was comparable to that of primary, fixed-bearing THA from several registries, which ranged from 0.7-1.1% at 5 to 16 years [1, 173, 174].

The modern, modular design has an additional cobalt-chromium (CoCr) liner inserted into a titanium acetabular component allowing supplementary screw fixation to enhance primary stability. However, the metal-on-metal interface between CoCr liner and titanium cup is at risk of fretting corrosion and remains a concern [175–177]. Metal ions can further lead to advanced local tissue reaction (ALRT) and implant loosening [178]. The first study regarding metal ions was conducted by Matsen Ko et al., which revealed 21% of the patient had elevated serum chromium levels [179]. Other studies reported that serum ion levels (cobalt, chromium or titanium) was elevated in 9.3-23% of the patients [47, 111]. On the other hand, some studies have noted that this elevation was not associated with clinical adverse events including instability, loosening or need of revision [64, 67, 72]. In summary, the current evidence suggests there is a slight elevation of serum ion level but this does not negatively affect the implant survival.

Intra-prosthetic dislocation (IPD) is a rare complication of DM design, which occurs as a result of retentive failure of the inner articulation. Long-term, homogenous PE wear or impingement at extreme range of motion between neck and PE liner leads to loss of PE retentive rim and IPD [180, 181]. The incidence of IPD ranged from 0.7%-4.3% in first generation of DM cup and [29, 30] modifications have been made to the 2nd generation DM implants. These changes include a thinner, more polished femoral neck to reduce impingement with the liner and the use of HXLPE to reduce wear during contact [32]. In this study, we noted a lower IPD rate with the modern design in primary THA and revision THA was 0.8% and 1.0% respectively, which is much lower than the 1st generation [29, 30]. Another form of IPD has been observed in modern generation DM implants, which often occurs in the short-term. This form of IPD results from a secondary decapsulation of the liner followed by reduction for dislocation [182]. During close reduction of a dislocated DM-THA, impingement occurs between the PE liner and the posterior edge of the acetabular component. The excessive loading during reduction maneuver may “decapsulate” the femoral head from PE liner. Therefore, the reduction should be performed gradually under general anesthesia to reduce excessive muscle tension [29].

Our meta-analysis showed that the mid-term revision rates in primary and revision DM-THA were 2.3% and 5.5-6.0%, respectively. These results were comparable to the reported outcome of primary or revision, fixed-bearing THA [1, 38, 39, 60, 73, 98, 108, 183, 184]. In primary fixed-bearing THA, the mid-term and long-term revision rate ranged from 1.2-4.0% and 12.1-14.3%, respectively [1, 38, 60, 73, 98, 108, 183]. In revision fixed-bearing THA, the mid-term and long-term revision rates can be up to 5.3-13% and 27-45%, respectively [39, 184].

This meta-analysis revealed promising mid-term outcomes and a reduction in dislocation rate, but the long-term implant survival of modern DM-THA is still lacking. For revision THA procedures, younger age and female patients were associated with a higher risk of implant failure. Younger patients have been established as a risk factor for failure after primary THAs. However, whether female sex is a risk factor remains controversial [185–188]. This can be attributed to the representativeness of the study cohort, follow-up duration and type of implant. Although female patients have been associated with increased risk of dislocation, aseptic loosening, periprosthetic fracture and overall implant failure after primary THA [187, 188], the same was not seen in DM-THA aside from overall implant failure. Potential confounders and inadequate follow-up duration are important considerations when interpreting this result.

We should recognize several limitations. First, we only included studies which the full text was available in English. In addition, due to the nature of our research question, the level of evidence of the included studies was low (III or IV). Second, we included studies that reported outcome of modern DM (the 2nd and 3rd generation) implants over a time span of 12 years between 2008 to 2020. Modern DM-THA implants were developed in the 1990s, and the studies about modern DM-THA implants were mostly conducted after 2000. We could only analyze factors that were clearly described in the studies, including
age, sex, surgical approach, BMI and indication for hip arthroplasty. Factors such as surgeons’ experience, patient activity level or implant designs could have affected the outcome but were unavailable and thus were not analyzed. Therefore, we considered articles that were conducted after 2000. Third, the protocol of this meta-analysis has not been registered, which can have a risk for reporting bias. Fourth, we did not include grey literature or unpublished studies in this work. Nonetheless, this review provides an updated review regarding the outcome of modern DM implants and factors that might affect the outcome.

Conclusions
In conclusion, the mid-term implant survival of modern dual-mobility design was satisfactory. Aseptic loosening continues to be the most common failure mode after DM-THA. Younger age and female sex were correlated with implant failure.

Abbreviations
DM: Dual mobility; THA: total hip arthroplasty; BMI: body mass index; IPD: intra-prosthetic dislocation; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-analysis; CI: confidence interval; CMA: Comprehensive Meta-Analysis; UHMWPE: ultra-high molecular weight polyethylene; HXLPE: highly cross-linked polyethylene; PE: polyethylene; CoCr: cobalt-chromium; ALRT: advance local tissue reaction

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12891-021-04404-4.

Funding
This work was financially supported by Mr. Morris Chang and Ms. Sophie Chang. The funding sources had no involvement and conflict of interests in this study.

Availability of data and materials
As this is a review and meta-analysis, we completed a comprehensive search on PubMed, MEDLINE, Cochrane Reviews and Embase for studies. All data generated or analysed during this study are included in this published article [and its supplementary information files]

Declarations
Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests

Author details
1Department of Orthopaedics and Traumatology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shi-Pai Road, Taipei 112, Taiwan. 2Department of Orthopaedics, School of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan. 3Chang Gung University College of Medicine, Taoyuan, Taiwan. 4Department of Orthopaedic Surgery, Chang-Gung Memorial Hospital, Chia-yi, Taiwan.

Received: 16 November 2020 Accepted: 24 May 2021
Published online: 14 June 2021

References
1. American Joint Replacement Registry. 2019 Sixth AJRR Annual Report on Hip and Knee Arthroplasty. Data. 2019; http://connect.ajrr.net/2019-ajrr-annual-report. Accessed 13 Sept 2020.
2. Bozic KJ, Kurtz SM, Lau E, Ong K, Vail TP, Berry DJ. The epidemiology of revision total hip arthroplasty in the United States. J Bone Joint Surg Am. 2009;91(1):128–33.
3. Berry DJ, von Knoch M, Schleck CD, Hammsen WS. Effect of femoral head diameter and operative approach on risk of dislocation after primary total hip arthroplasty. J Bone Joint Surg Am. 2005;87(11):2456–63.
4. Parvizi J, Picincic E, Sharkey PF. Revision total hip arthroplasty for instability: surgical techniques and principles. J Bone Joint Surg Am. 2008;90(5):1134–42.
5. Berend KR, Sporer SM, Siera RJ, Glassman AH, Morris MJ. Achieving stability and lower-limb length in total hip arthroplasty. J Bone Joint Surg Am. 2010;92(16):2737–52.
6. Parvizi J, Picincic E, Sharkey PF. Revision total hip arthroplasty for instability: surgical techniques and principles. Instr Course Lect. 2009;58:183–91.
7. Witters NG, Munay TG, Moric M, Sporer SM, Papsosky WG, Delta Valle CJ. Risk factors for dislocation after revision total hip arthroplasty. Clinical Orthopaedics and Related Research. 2013;471(2):410–6.
8. Delaunay C, Hamadouche M, Girard J, Duhamel A, So FG. What are the causes for failures of primary hip arthroplasties in France? Clinical Orthopaedics and RELATED Research. 2013;471(12):3863–9.
9. Newington DP, Bannister GC, Fordyce M. Primary total hip replacement in patients over 80 years of age. The Journal of Bone and Joint Surgery British. 1999;72(3):450–2.
10. Woolston SR, Rahimtoola ZO. Risk factors for dislocation during the first 3 months after primary total hip replacement. J Arthroplasty. 1999;14(6):662–8.
11. Davis AM, Wood AM, Keenan AC, Brenchel UI, Ballantyne JA. Does body mass index affect clinical outcome post-operatively and at five years after primary unilateral total hip replacement performed for osteoarthritis? A multivariate analysis of prospective data. The Journal of Bone and Joint Surgery British. 2011;93(9):1178–82.
12. Kim Y, Morshed S, Joseph T, Bozic K, Ries MD. Clinical impact of obesity on stability following revision total hip arthroplasty. Clinical Orthopaedics and Related Research. 2006;453:142–6.
Iorio R, Iannotti F, Mazza D, Speranza A, Massafra C, Guzzini M, et al. Dual-mobility cups in total hip arthroplasty after failed internal fixation of proximal femoral fractures. Orthopaedics & Traumatology, Surgery & Research : OTSR. 2019;105(3):491–5.

Boulot S, Neri T, Boyer B, Philippot R, Farizon F. Dual mobility cups in total hip arthroplasty after failed internal fixation of proximal femoral fractures. Orthopaedics & Traumatology, Surgery & Research : OTSR. 2019;105(3):491–5.

Bloemheuvel EM, van Steenbergen LN, Swierstra BA. Dual mobility cups in primary total hip arthroplasties: trend over time in patient characteristics, and mid-term revision in 3,038 cases in the Dutch Arthroplasty Register (2007-2016). Acta Orthop. 2019;90(1):11–4.

Bloemheuvel EM, Steenbergen LN, Swierstra BA. Lower 5-year cup re-revision rate for dual mobility cups compared with unipolar cups: report of 15,022 cup revision cases in the Dutch Arthroplasty Register (2007-2016). Acta Orthop. 2019;90(4):338–41.

Assi C, Barakat H, Mansour J, Samaha C, Yammine K. Primary total hip arthroplasty: mid-term outcomes of dual-mobility cups in patients at high risk of dislocation. Hip Int. 2019;31(2):301–7.

Addona JL, Gu A, De Martino I, Malahas MA, Sculpo TP, Sculpo PK. High rate of early intraoperative dislocations of dual mobility implants: a single surgeon prospchem of series of revision and primary total hip replacements. J Arthroplasty. 2019;34(11):2793–8.

Chalmers BP, Mangold DG, Hansson AD, Pagnano MW, Trousdale RT, Abdel MP. Uniformly low serum cobalt levels at 24 months after modular dual-mobility total hip arthroplasties with ceramic heads: a prospective study in high-risk patients. Bone Joint J. 2019;101-B(5 Suppl_B):57–61.

Dubin JA, Westrich GH. Anatomic dual mobility compared to modular dual mobility in primary total hip arthroplasty: a matched cohort study. Arthroplast Today. 2019;5(4):569–74.

Schmidt-Bräkling T, Sieber D, Goseberger G, Theil JC, Moellenbeck B, Andreou D, et al. Dislocation rates with combinations of anti-protrusio cages and dual mobility cups in revision cases: Are we safe? PloS one. 2019;14(2):e021072.

Markel DC, Bou-Akl T, Rossi MD, Pizzimonti N, Wu B, Ren W. Blood metal levels, leukocyte profiles, and cytokine profiles in patients with a modular dual-mobility hip prosthesis: early results from a prospective cohort study. Bone Joint J. 2019;101-B(8):1035–41.

Colacchio ND, Wooten CJ, Martin JR, Masonis JL, Fehring TK. Dual mobility for monoblock metal-on-metal revision-is it safe? J Arthroplasty. 2020;35(2):508–12.

Laende BK, Richardson CG, Dunbar MJ. Migration and wear of a dual mobility acetabular construct at 3 years measured by radiostereometric analysis. J Arthroplasty. 2020;35(4):1109–16.

Ulkaj S, Znun O, Ulkaj F, Podvorica V, Grezda K, Caton J, et al. Dual mobility acetabular cup versus hemiarthroplasty in treatment of displaced femoral fractures in elderly patients: comparative study and results at minimum 3-year follow-up. Geriatr Orthop Surg Rehabil. 2019;10(1):2151459319848610.

Nonne D, Sanna F, Bardelli A, Miliano P, Rivera F. Use of a dual mobility cup to prevent hip early arthroplasty dislocations in patients at high falls risk. Injury. 2019;50(Suppl 4):S26–59.

Nam D, Salih R, Nahhas CR, Barrack RL, Nunley RM. Is a modular dual mobility acetabulum a viable option for the young, active total hip arthroplasty patient? Bone Joint J. 2019;101-B(4):365–71.

Heipke P, Rogmark C, Pedersen AB, Karholm J, Hallen C, Havelin LI, et al. Dual mobility cups: effect on risk of revision primary total hip arthroplasty due to osteoarthritis: a matched population-based study using the Nordic arthroplasty register association database. The Journal of Bone and Joint Surgery American. 2019;101(2):169–76.

Jobory A, Karholm J, Overgaard S, Becic Pedersen A, Hallan G, Gjersten JE, et al. Reduced revision risk for dual-mobility cup in total hip replacement due to hip fracture: a matched-pair analysis of 9,040 cases from the Nordic Arthroplasty Register Association (NARA). The Journal of Bone and Joint Surgery American. 2019;101(4):1278–85.

Iorio R, Iannotti F, Mazza D, Speranza A, Massafra C, Guzzini M, et al. Is dual cup mobility better than hemiarthroplasty in patients with dementia and femoral neck fracture? A randomized controlled trial. SicOT. 2019;5:38.
nich and chromium levels with 29 months' follow-up. Orthopaedics & Traumatology, Surgery & Research: OTSR. 2018;10:8(1):1179–82.

97. Boukheus B, Boutroux P, Zahi R, Azy C, Guillon P. Comparison of dual mobility total hip arthroplasty and bipolar arthroplasty for femoral neck fractures: A retrospective case-control study of 199 hips. Orthopaedics & Traumatology, Surgery & Research: OTSR. 2018;10:3(3):369–75.

98. Tarasievsic T, Smalys A, Grigaitis K, Robertson S, Stucinski S. Short-term outcome after total hip arthroplasty using dual-mobility cup: report from Lithuanian Arthroplasty Register. International Orthopaedics. 2017;41(3):595–8.

99. Sutter EG, McClellan TR, Attarian DE, Bolognese MP, Lachiewicz PF, Wellman SS. Outcomes of modular dual mobility acetabular components in revision total hip arthroplasty. J Arthroplasty. 2017;32(9):220–5.

100. Lebeau N, Bayle M, Bellouaudine R, Chell J, Havet E, Brunschweiler B, et al. Total hip arthroplasty revision by dual-mobility acetabular cup cemented in a metal reinforcement: A 62 case series at a minimum 5 years’ follow-up. Orthopaedics & Traumatology, Surgery & Research: OTSR. 2017;10:3(5):679–84.

101. Heras AT, Abdel BA. Dual mobility total hip arthroplasty in hemipelvic patients. SICOT J. 2017;3:40.

102. Chalmers BP, Perry KI, Hanssen AD, Pagnano MW, Abdel MP. Conversion of hip hemiarthroplasty to total hip arthroplasty utilizing a dual-mobility construct compared with large femoral head. J Arthroplasty. 2017;32(10):3071–5.

103. Ferreira A, Prudhon JL, Verdier R, Puch JM, Descamps L, Dehrli G, et al. Contemporary dual-mobility cup regional and private registry: methodology and results. International Orthopaedics. 2017;41(3):439–45.

104. Kasparek MF, Renner L, Faschingbauer M, Waldstein W, Neyret P, Lustig S. Total hip arthroplasty using direct anterior approach and dual mobility cup: safe and efficient strategy against post-operative dislocation. International Orthopaedics. 2017;41(3):499–506.

105. Ochi H, Baba T, Homma Y, Matsumoto M, Wazari T, Ozaki Y, et al. Total hip arthroplasty via the direct anterior approach with a dual mobility cup for displaced femoral neck fracture in patients with a high risk of dislocation. SICOT J. 2017;3:56.

106. Gaversen AE, Jakobsen SS, Kristensen PK, Thillemann TM. No dislocations after primary hip arthroplasty with the dual mobility cup in displaced femoral neck fracture in patients with dementia. A one-year follow-up in 20 patients. SICOT J. 2017;3:9.

107. Perrin A, Saab M, Putman M, Benad K, Drumez E, Chantelot C. The benefit of the systematic revision of the acetabular implant in favor of a dual mobility articulation during the treatment of periprosthetic fractures of the femur: a 49 cases prospective comparative study. European Journal of Orthopaedic Surgery & Traumatology: Orthopede. Traumatologie. 2018;282(239):46–60.

108. Rowan FE, Salvatore AJ, Lange JK, Westrich GH. Dual-mobility vs fixed-bearing total hip arthroplasty in patients under 55 years of age: a single-institution, matched-cohort analysis. J Arthroplasty. 2017;32(10):3076–81.

109. Spaans EA, Koenaardt KLM, Wagenmakers R, van den Hout J, Te Stroet MAJ, Bolder SBT. Midterm survival analysis of a cemented dual-mobility cup combined with bone impaction grafting in 102 revision hip arthroplasties. Hip Int. 2018;28:2(1):161–7.

110. Batailler C, Fary C, Batailler P, Serien E, Neyret P, Lustig S. Total hip arthroplasty using direct anterior approach and dual mobility cup: safe and efficient strategy against post-operative dislocation. International Orthopaedics. 2017;41(3):499–506.

111. Nam D, Salih R, Brown KM, Nunley RM, Barrack RL. Metal ion levels in young, active patients receiving a modular, dual mobility total hip arthroplasty and bipolar arthroplasty for femoral neck fracture: A prospective longitudinal study. International Orthopaedics. 2017;41(3):543–50.

112. Griffin XL, Parsons N, Achten J, Costa ML. A randomised feasibility study comparing total hip arthroplasty with and without dual mobility acetabular component in the treatment of displaced intracapsular fractures of the proximal femur: The Warwick Hip Trauma Evaluation Two: WHITE Two. Bone Joint J. 2016;88-B(11):1431–5.
persistent dislocation: no dislocations in 50 hips after 1-5 years. Journal of orthopaedics and Traumatology : Official Journal of the Italian Society of Orthopaedics and Traumatology. 2015;16(1):15–20.

136. Siman E, Chatellier R, Dunn J, Berhouet J, Rosset P. Dual mobility cup in revision total hip arthroplasty: dislocation rate and survival after 5 years. Orthopaedics & Traumatology, Surgery & Research : OTSR. 2015;10(5):577–81.

137. Mohrmed R, Hayward K, Mulay S, Bindi F, Wallace M. Outcomes of dual-mobility acetabular cup for instability in primary and revision total hip arthroplasty. Journal of Orthopaedics and Traumatology : Official Journal of the Italian Society of Orthopaedics and Traumatology. 2015;16(19–13).

138. Epinette JA. Clinical outcomes, survivorship and adverse events with mobile-bearings versus fixed-bearings in hip arthroplasty: a prospective comparative cohort study of 143 ADM versus 130 trident cups at 2 to 6-year follow-up. J Arthroplasty. 2015;30(2):241–8.

139. Bel JC, Carret JP. Total hip arthroplasty with minimal invasive surgery in elderly patients with neck of femur fractures: our institutional experience. Injury. 2015;46(Suppl 1):S13–7.

140. Wegrzyn J, Pibarot V, Jacquet A, Carret JP, Bejui-Hugues J, Guyen O. Acetabular reconstruction using a Kerboull cross-plate, structural allograft and cemented dual-mobility cup in revision THA at a minimum 5-year follow-up. J Arthroplasty. 2014;29(2):432–7.

141. Prudhon JL, Steffann F, Ferreira A, Verdier R, Aslanian T, Caton J. Cementless dual-mobility cup in total hip arthroplasty revision. International Orthopaedics. 2014;38(12):2463–8.

142. Jakobes T, Kappel A, Hansen F, Karup N. The dislocating hip replacement - revision with a dual mobility cup in 56 consecutive patients. Open Orthop J. 2014;8:268–71.

143. Epinette JA, Beracassat R, Tracol P, Pagazani G, Vandenbussche E. Are modern dual mobility cups a valuable option in reducing instability after primary hip arthroplasty, even in younger patients? J Arthroplasty. 2014;29(6):1322–3.

144. Caton JH, Prudhon JL, Ferreira A, Aslanian T, Verdier R. A comparative and retrospective study of three hundred and twenty primary Charnley type hip replacements with a minimum follow up of ten years to assess whether a dual mobility cup has a decreased dislocation risk. International Orthopaedics. 2014;38(6):1125–9.

145. Bensen AS, Jakobes T, Karup N. Dual mobility cup reduces dislocation and re-operation when used to treat displaced femoral neck fractures. International Orthopaedics. 2014;38(6):1241–8.

146. Tarasevicius S, Robertson O, Busevicius M, Robertsson O, Wingstrand H. Dual mobility cup reduces dislocation rate after arthroplasty for femoral neck fracture. BMC Musculoskelet Disord. 2010;11:175.

147. Hamadouche M, Blau DJ, Huten D, Musset T, Gaucher F. The use of a cemented dual mobility socket to treat recurrent dislocation. Clinical Orthopaedics and Related Research. 2010;468(12):3248–54.

148. Guyen O, Pibarot V, Vaz G, Chevillotte C, Bejui-Hugues J. Use of a dual mobility socket to manage total hip arthroplasty instability. Clinical Orthopaedics and Related Research. 2009;467(2):465–72.

149. Langlas FL, Ropan M, Gaucher F, Musset T, Chiak O. Dual mobility cemented cups have low dislocation rates in THA revisions. Clinical Orthopaedics and Related Research. 2008;466(2):389–95.

150. Bauchu P, Bonnard O, Cyprés A, Fiquet A, Girardin P, Noyer D. The dual-mobility POLARCUP: first results from a multicenter study. Orthopedics. 2008;31(12 Suppl 2).

151. Pattyn C, Audenaert E. Early complications after revision total hip arthroplasty with cemented dual-mobility socket and reinforcement ring. Acta Orthop Belg. 2012;78(3):357–61.

152. Narukuty NL, Middleton RC, Matthews EC, Young PS, Uzolozje CE, Minhas TH. The double-mobility acetabular component in revision total hip replacement: the United Kingdom experience. The Journal of Bone and Joint Surgery British. 2012;94(5):603–8.

153. Snir N, Park BK, Garlofo G, Marwin SE. Revision of failed hip resurfacing and large metal-on-metal total hip arthroplasty using dual-mobility components. Orthopedics. 2015;38(6):369–74.

154. Gaudin G, Ferreira A, Galillard R, Prudhon JL, Caton JH, Lustig S. Equivalent wear performance of dual mobility bearing compared with standard bearing in total hip arthroplasty: in vitro study. International Orthopaedics. 2017;41(3):521–7.

155. Geringer J, Boyer B, Farizon F. Understanding the dual mobility concept for total hip arthroplasty. Investigations on a multiscale analysis-highlighting the role of arthrofriction. Wear. 2011;271(9):2379–85.

156. Imbert L, Geringer J, Boyer B, Farizon F. Wear analysis of hip explants, dual mobility concept: Comparison of quantitative and qualitative analyses. Proceedings of the Institution of Mechanical Engineers, Part J: Journal of Engineering Tribology. 2011;226(10):838–53.

157. Boyer B, Neri T, Geringer J, Di Iorio A, Philippot R, Farizon F. Long-term wear of dual mobility total hip replacement cups: explant study. International Orthopaedics. 2018;42(1):1–7.

158. Boyer B, Neri T, Geringer J, Di Iorio A, Philippot R, Farizon F. Understanding wear in dual mobility total hip replacement: first generation explant wear patterns. International Orthopaedics. 2017;41(3):529–33.

159. Boyer B, Neri T, Di Iorio A, Geringer J, Philippot R, Farizon F. The linear penetration rate is not relevant for evaluating wear of dual mobility cups: an explant study. International Orthopaedics. 2017;41(3):599–603.

160. Loving L, Herrera L, Banejee S, Heffeman C, Nevelos J, Markel DC, et al. Dual mobility bearings withstand loading from steeper cup-inclinations without substantial wear. J Orthop Res. 2015;33(3):398–404.

161. Callary SA, Solomon LB, Holubowycz OT, Campbell DG, Munn Z, Howie DW. Wear of highly crosslinked polyethylene acetabular components. Acta Orthop. 2015;86(2):159–68.

162. Deckard ER, Azzam KA, Meneghini RM. Contemporary Dual Mobility Head and Cemented Cups Component: Comparison of Quantitative and Qualitative Analyses. Engineering Tribology. 2012;226(10):838–53.

163. Snir N, Park BK, Garlofo G, Marwin SE. Revision of failed hip resurfacing and large metal-on-metal total hip arthroplasty using dual-mobility components. Orthopedics. 2015;38(6):369–74.

164. Gaudin G, Ferreira A, Galillard R, Prudhon JL, Caton JH, Lustig S. Equivalent wear performance of dual mobility bearing compared with standard bearing in total hip arthroplasty: in vitro study. International Orthopaedics. 2017;41(3):521–7.

165. Geringer J, Boyer B, Farizon F. Understanding the dual mobility concept for total hip arthroplasty. Investigations on a multiscale analysis-highlighting the role of arthrofriction. Wear. 2011;271(9):2379–85.

166. Imbert L, Geringer J, Boyer B, Farizon F. Wear analysis of hip explants, dual mobility concept: Comparison of quantitative and qualitative analyses. Proceedings of the Institution of Mechanical Engineers, Part J: Journal of Engineering Tribology. 2011;226(10):838–53.

167. Boyer B, Neri T, Geringer J, Di Iorio A, Philippot R, Farizon F. Long-term wear of dual mobility total hip replacement cups: explant study. International Orthopaedics. 2018;42(1):1–7.

168. Boyer B, Neri T, Geringer J, Di Iorio A, Philippot R, Farizon F. Understanding wear in dual mobility total hip replacement: first generation explant wear patterns. International Orthopaedics. 2017;41(3):529–33.

169. Boyer B, Neri T, Di Iorio A, Geringer J, Philippot R, Farizon F. The linear penetration rate is not relevant for evaluating wear of dual mobility cups: an explant study. International Orthopaedics. 2017;41(3):599–603.

170. Loving L, Herrera L, Baneej S, Heffeman C, Nevelos J, Markel DC, et al. Dual mobility bearings withstand loading from steeper cup-inclinations without substantial wear. J Orthop Res. 2015;33(3):398–404.

171. Callary SA, Solomon LB, Holubowycz OT, Campbell DG, Munn Z, Howie DW. Wear of highly crosslinked polyethylene acetabular components. Acta Orthop. 2015;86(2):159–68.

172. Deckard ER, Azzam KA, Meneghini RM. Contemporary Dual Mobility Head and Cemented Cups Component: Comparison of Quantitative and Qualitative Analyses. Engineering Tribology. 2012;226(10):838–53.
176. Hothi HS, Ilo K, Whittaker RK, Eskelinen A, Skinner JA, Hart AJ. Corrosion of metal modular cup liners. J Arthroplasty. 2015;30(9):1652–6.
177. Kolz JM, Wyles CC, Van Citters DW, Chapman RM, Trousdale RT, Berry DJ. In vivo corrosion of modular dual-mobility implants: a retrieval study. J Arthroplasty. 2020.
178. Wiley KF, Ding K, Stoner JA, Teague DC, Yousuf KM. Incidence of pseudotumor and acute lymphocytic vasculitis associated lesion (ALVAL) reactions in metal-on-metal hip articulations: a meta-analysis. J Arthroplasty. 2013;28(7):1238–45.
179. Matsen Ko Ll, Pollag KE, Yoo JY, Sharkey PF. Serum metal ion levels following total hip arthroplasty with modular dual mobility components. J Arthroplasty. 2016;31(1):186–9.
180. D’Apuzzo MR, Koch CN, Esposito CI, Elpers ME, Wright TM, Westrich GH. Assessment of damage on a dual mobility acetabular system. J Arthroplasty. 2016;31(8):1828–35.
181. Neri T, Boyer B, Geringer J, Di Iorio A, Caton JH, Philippot R, et al. Intraprosthetic dislocation of dual mobility total hip arthroplasty: still occurring? International Orthopaedics. 2019;43(5):1097–105.
182. De Martino J, D’Apulito R, Waddell BS, McLawhorn AS, Sculco PK, Sculco TP. Early intraprosthetic dislocation in dual-mobility implants: a systematic review. Arthroplast Today. 2017;3(3):197–202.
183. Evans JT, Evans JP, Walker RW, Blom AW, Whitehouse MR, Sayers A. How long does a hip replacement last? A systematic review and meta-analysis of case series and national registry reports with more than 15 years of follow-up. Lancet. 2019;393(10172):647–54.
184. Van Eecke E, Vanbiervliet J, Daude J, Muller M. Comparison of constrained acetabular components and dual mobility cups in revision total hip arthroplasty: a literature review. Hip Pelvis. 2020;32(2):59–69.
185. Wright EA, Katz JN, Baron JA, Wright RI, Malchau H, Mahomed N, et al. Risk factors for revision of primary total hip replacement: results from a national case-control study. Arthritis Care Res (Hoboken). 2012;64(12):1879–85.
186. Prokopetz JJ, Losina E, Bliss RL, Wright J, Baron JA, Katz JN. Risk factors for revision of primary total hip arthroplasty: a systematic review. BMC Musculoskeletal Disord. 2012;13:251.
187. Inacio MC, Ake CF, Paxton EW, Khatod M, Wang C, Gross TP, et al. Sex and risk of hip implant failure: assessing total hip arthroplasty outcomes in the United States. JAMA Intern Med. 2013;173(6):435–41.
188. Karachalios T, Kominos G, Koutalos A. Total hip arthroplasty: Survival and modes of failure. EFORT Open Rev. 2018;3(3):232–9.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.